Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee

September 6, 2002

Slides

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Introduction and overview, Dr. Burkhard Blank, MD, Boehringer Ingelheim Pharmaceuticals, Inc.  htm  ppt

Spiriva (tiotropium bromide) Inhalation Powder, Dr. Lisa Kammerman, PhD, FDA  htm   ppt

Spiriva (tiotropium bromide) Inhalation Powder, Dr. Eugene Sullivan, MD FCCP, FDA   htm   ppt

Questions for the Committee   htm  ppt

Backup Slides  htm   ppt

Open Public Hearing

Public Comments  pdf